Drugs / LP-284
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06132503 | Jan 2023 → Nov 2028 expected | lymphoma | Lantern Pharma Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2026-01-20 | Lantern Pharma Inc. | Regulatory Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas lanternpharma.com ↗
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LP-284 for the treatment of soft tissue sarcomas. |
| 2025-10-28 | Lantern Pharma Inc. | Results Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers. lanternpharma.com ↗
AI-advanced drug candidate achieves complete metabolic response after two cycles in patient who failed CAR-T and bispecific antibody therapies, validating LP-284’s mechanism of action. |
| 2025-07-23 | Lantern Pharma Inc. | Results Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial lanternpharma.com ↗
Following enrollment in April 2025, the patient achieved complete metabolic response with non-avid lesions after completing just two 28-day cycles of LP-284 administered on days one, eight, and 15. |
| 2023-11-30 | Lantern Pharma Inc. | Regulatory FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL) lanternpharma.com ↗
This Orphan Drug Designation marks the second such designation for drug-candidate LP-284 this year. |
| 2023-09-18 | Lantern Pharma Inc. | Regulatory Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas lanternpharma.com ↗
today announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for LP-284. |
| 2023-06-26 | Lantern Pharma Inc. | Results Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin’s Lymphomas lanternpharma.com ↗
today announced the company has published new findings in Oncotarget demonstrating drug candidate LP-284’s in vitro and in vivo antitumor potency for multiple non-Hodgkin’s lymphomas (NHL), including mantle cell lymphoma (MCL) and double-hit lymphoma (DHL). |
| 2023-01-05 | Lantern Pharma Inc. | Regulatory FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma lanternpharma.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has granted LP-284 Orphan Drug Designation (ODD) for the treatment of mantle cell lymphoma (MCL). |
| 2022-12-15 | Lantern Pharma Inc. | Results Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting lanternpharma.com ↗
The ASH poster highlights new results for LP-284 from preclinical studies for MCL and initial results from investigational new drug (IND) enabling studies. |
| 2021-12-14 | Lantern Pharma Inc. | Results Lantern Pharma Presents Positive Data on the Effectiveness of LP-284 in Hematologic Cancers at the 63rd American Society of Hematology (ASH) Annual Meeting lanternpharma.com ↗
The study demonstrated LP-284's broad in vitro anti-tumor activity in lymphoma, multiple myeloma, and leukemia cells. |
All press releases naming this drug 17 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LP-284 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06132503 ↗ |
| Modality | Small molecule | “LP-284 is a small molecule alkylating agent causing tumor cell death through DNA damage.” NCT06132503 ↗ |
| Route | Intravenous | “LP-284 administered intravenously (IV)” NCT06132503 ↗ |